CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,822,523 | -82.1% | 189,304 | -86.9% | 0.00% | -87.5% |
| Q2 2023 | $15,811,734 | +61386.0% | 1,443,994 | -51.0% | 0.01% | -46.7% |
| Q1 2023 | $25,716 | +340.9% | 2,949,056 | +217.0% | 0.02% | +400.0% |
| Q4 2022 | $5,832 | -99.9% | 930,188 | -39.4% | 0.00% | 0.0% |
| Q3 2022 | $5,369,000 | -39.6% | 1,533,982 | -49.1% | 0.00% | -50.0% |
| Q2 2022 | $8,896,000 | +20.6% | 3,015,496 | +27.1% | 0.01% | +50.0% |
| Q1 2022 | $7,379,000 | +5.4% | 2,372,700 | +14.6% | 0.00% | 0.0% |
| Q4 2021 | $6,999,000 | -2.1% | 2,070,787 | +5.7% | 0.00% | 0.0% |
| Q3 2021 | $7,149,000 | -28.8% | 1,958,653 | -14.9% | 0.00% | -42.9% |
| Q2 2021 | $10,040,000 | +2.7% | 2,302,812 | +6.9% | 0.01% | 0.0% |
| Q1 2021 | $9,778,000 | +24.7% | 2,153,779 | +57.7% | 0.01% | +16.7% |
| Q4 2020 | $7,841,000 | -36.4% | 1,366,048 | -19.8% | 0.01% | -60.0% |
| Q3 2020 | $12,326,000 | +318.5% | 1,702,403 | +101.7% | 0.02% | +275.0% |
| Q2 2020 | $2,945,000 | +27.8% | 843,957 | -45.8% | 0.00% | -20.0% |
| Q1 2020 | $2,305,000 | -60.7% | 1,557,140 | -48.0% | 0.01% | -28.6% |
| Q4 2019 | $5,868,000 | -69.2% | 2,993,645 | -19.6% | 0.01% | -76.7% |
| Q3 2019 | $19,065,000 | -10.7% | 3,723,797 | +24.8% | 0.03% | -6.2% |
| Q2 2019 | $21,361,000 | -5.5% | 2,983,417 | +75.3% | 0.03% | -5.9% |
| Q1 2019 | $22,599,000 | +146.9% | 1,701,700 | +46.3% | 0.03% | +142.9% |
| Q4 2018 | $9,154,000 | -9.2% | 1,163,152 | +27.9% | 0.01% | +16.7% |
| Q3 2018 | $10,080,000 | -35.7% | 909,775 | -22.2% | 0.01% | -40.0% |
| Q2 2018 | $15,683,000 | +4.1% | 1,168,632 | +0.7% | 0.02% | 0.0% |
| Q1 2018 | $15,072,000 | +2395.4% | 1,160,275 | +1666.5% | 0.02% | +1900.0% |
| Q4 2017 | $604,000 | -95.6% | 65,681 | -96.1% | 0.00% | -95.2% |
| Q3 2017 | $13,727,000 | +459.6% | 1,703,124 | +299.9% | 0.02% | +425.0% |
| Q2 2017 | $2,453,000 | +1395.7% | 425,898 | +1017.4% | 0.00% | – |
| Q1 2017 | $164,000 | – | 38,115 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 1,653,495 | $10,367,414 | 8.97% |
| Versant Venture Management, LLC | 543,753 | $3,409,330 | 7.06% |
| TCG Crossover Management, LLC | 5,905,400 | $37,026,858 | 6.54% |
| COMMODORE CAPITAL LP | 5,738,500 | $35,980 | 5.42% |
| Foresite Capital Management IV, LLC | 1,787,094 | $11,205,079 | 4.79% |
| Saturn V Capital Management LP | 1,611,778 | $5,718,432 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 1,015,000 | $6,364,050 | 3.92% |
| Altium Capital Management LP | 1,025,000 | $6,426,750 | 3.27% |
| Affinity Asset Advisors, LLC | 1,143,531 | $7,169,939 | 2.81% |
| GREAT POINT PARTNERS LLC | 1,550,000 | $9,718,500 | 1.90% |